OPHI CollPlant Biotechnologies Ltd
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1631487 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY360.4%
TTM net income YoY30.8%
TTM EPS YoY35.2%
Revenue 3-yr CAGR99.4%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-484.3%
Net margin-484.6%
FCF margin-398.4%
EBITDA margin-445.8%
Returns
ROE-117.6%
ROA-77.9%
ROIC (approx.)-886.8%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.00x
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.37M | $515,000 | $10.96M | $299,000 | $15.64M |
| Cost of revenue | $835,000 | $1.62M | $1.99M | $400,000 | $2.00M |
| Gross profit | $1.54M | -$1.11M | $8.97M | -$101,000 | $13.64M |
| R&D expense | $8.19M | $10.52M | $10.48M | $10.26M | $7.63M |
| SG&A expense | $4.83M | $5.63M | $6.00M | $6.74M | $5.94M |
| Operating income | -$11.48M | -$17.25M | -$7.51M | -$17.10M | $65,000 |
| Income tax | — | $45.99M | $59.99M | — | — |
| Net income | -$11.49M | -$16.61M | -$7.02M | -$16.93M | $237,000 |
| EBITDA | -$10.57M | -$16.21M | -$6.41M | -$16.02M | $838,000 |
| EPS (basic) | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 |
| EPS (diluted) | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 |
| Weighted avg. shares (diluted) | 12.20M | 11.45M | 11.39M | 11.03M | 11.97M |
| Balance sheet | |||||
| Cash & equivalents | $5.59M | $11.91M | $26.67M | $29.86M | $13.37M |
| Receivables | $1,000 | $150,000 | — | $9,000 | $270,000 |
| Inventory | $573,000 | $440,000 | $714,000 | $1.43M | $1.08M |
| Current assets | $6.75M | $13.18M | $28.02M | $31.66M | $45.09M |
| PP&E, net | $1.46M | $2.29M | $2.79M | $2.97M | $2.73M |
| Intangibles | $73,000 | $131,000 | $188,000 | $245,000 | $243,000 |
| Total assets | $10.79M | $18.71M | $34.13M | $37.77M | $51.22M |
| Current liabilities | $2.67M | $2.97M | $3.25M | $3.10M | $3.01M |
| Short-term debt | — | — | — | $321,000 | $219,000 |
| Long-term debt | — | — | — | — | $30,000 |
| Total debt | — | — | — | — | $249,000 |
| Total liabilities | $4.70M | $5.25M | $5.79M | $5.49M | $6.10M |
| Shareholders' equity | $6.08M | $13.46M | $28.34M | $32.28M | $45.12M |
| Net debt | — | — | — | — | -$13.12M |
| Shares outstanding | 12.80M | 11.45M | 11.45M | 11.19M | 10.77M |
| Cash flow statement | |||||
| Operating cash flow | -$9.42M | -$14.09M | -$2.76M | -$13.70M | $2.50M |
| Capital expenditure | $28,000 | $483,000 | $954,000 | $1.27M | $1.43M |
| Free cash flow | -$9.45M | -$14.58M | -$3.72M | -$14.97M | $1.07M |
| Investing cash flow | -$27,000 | -$539,000 | -$1.16M | $28.92M | -$31.56M |
| Financing cash flow | $3.10M | $9,000 | $1.11M | $1.87M | $38.76M |
| Depreciation & amortization | $912,000 | $1.04M | $1.10M | $1.08M | $773,000 |
| Stock-based compensation | $999,000 | $1.72M | $1.94M | $2.17M | $1.60M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.